J. W. Boag, “Maximum Likelihood Estimates of the Proportion of Patients Cured by Cancer Therapy,” Journal of the Royal Statistical Society: Series B (Methodological), Vol. 11, No. 1, 1949, pp. 15-53.
 D. Sargent, A. Sobrero, A. Grothey, M. J. O’Connell, M. Buyse, et al., “Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data from 20, 898 Patients on 18 Randomized Trials,” Journal of Clinical Oncology, Vol. 27, No. 6, 2009, pp. 812-877. http://dx.doi.org/10.1200/ JCO.2008.19.5362
 X. Paoletti and B. Asselain, “Surgical Analysis in Clinical Trials: Old Tools or New Techniques,” Surgical Oncology, Vol. 19, No. 2, 2010, pp. 55-58. http://dx.doi.org/10.1016/j.suronc.2010.01.004
 E. Romond, E. A. Perez, J. B. Bryant, V. J. Surman, V. J. Suman, et al., “Trastzumab plus Adjuvant Chemotherapy for Operable HER-Positive Breast Cancer,” The New England Journal of Medicine, Vol. 353, 2005, pp. 1673-1684. http://dx.doi.org/10.1056/NEJMoa052122
 L. G. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas, A. Lluch, et al., “Neoadjuvant Chemotherapy with Trastuzumab Followed by Adjuvanttrastuzumab versus Neoadjuvant Chemotherapy Alone, in Patients with HER2-Positive Locally Advanced Breast Cancer (the NOAH Trial): A Randomized Controlled Superiority Trial with a Parallel HER2-Negative Cohort,” Lancet, Vol. 375, No. 9712, 2010, pp. 377-384. http://dx.doi.org/10.1016/S0140-6736(09)61964-4
 R. Peto, M. C. Pike, P. Armitage, N. E. Breslow, D. R. Cox, et al., “Design and Analysis of Randomized Clinical Trials Requiring Prolonged Observation of Each Patient: Part 2. Analysis and Examples,” British Journal of Cancer, Vol. 35, 1977, pp. 1-39. http://dx.doi.org/10.1038/bjc.1977.1
 T. G. Clark, M. J. Bradburn, S. B. Love and D. G. Altman, “Survival Analysis Part I: Basic Concepts and First Analyses,” British Journal of Cancer, Vol. 89, 2003, pp. 232-238. http://dx.doi.org/ 10.1038/sj.bjc.6601118
 E. J. Freireich, E. Gehan, E. Frei, et al., “The Effect of 6-Mercaptopurine on the Duration of Steroid-Induced Remission in Acute Leukemia: A Model for Evaluation of Other Potentially Useful Therapy,” Blood, Vol. 21, No. 6, 1963, pp. 699-716.
 S. Maetani and J. W. Gamel, “Paranetric Cancer Survival Analysis Using the Boag Model: A Clinician’s View,” Journal of Biometrics & Biostatistics, Vol. 3, 2012, p. 3. http://dx.doi.org/10.4172/2155-6180.1000140
 G. J. D’angio and T. J. Vietti, “Old Man River: The Flow of Pediatric Oncology,” Hematology/Oncology Clinics of North America, Vol. 15, No. 4, 2001, pp. 599-607. http://dx.doi.org/10.1016/S0889-8588(05)70238-0
 J. W. Gamel and I. W. McLean, “A Stable, Multivariate Extension of the Log-Normal Survival Model,” Computers and Biostatistical Research, Vol. 27, No. 2, 1994, pp. 148-155. http://dx.doi.org/ 10.1006/cbmr.1994.1014
 J. W. Gamel, E. A. Weller, M. N. Wesley, et al., “Parametric Cure Models of Relative and Cause-Specific Survival for Grouped Survival Times,” Computer Methods and Programs in Biomedicine, Vol. 61, No. 2, 2000, pp. 90-110. http://dx.doi.org/10.1016/S0169-2607(99)00022-X
 B. Yu, R. C. Tiwari, K. A. Cronin, et al., “CANSURV: A Windows Program for Population-Based Cancer Survival Analysis,” Computer Methods and Programs in Biomedicine, Vol. 80, No. 3, 2005, pp. 195-203. http://dx.doi.org/10.1016/j.cmpb.2005.08.002
 J. W. Gamel, R. L. Vogel, P. Valagussa and G. Bonadonna, “Parametric Survival Analysis of Adjuvant Therapy for Stage II Breast Cancer,” Cancer, Vol. 74, No. 9, 1994, pp. 2483-2490. http://dx.doi.org/10.1002/1097-0142(19941101)74:9<2483::AID-CNCR2820740915>3.0.CO;2-3
 G. Bonadonna and P. Valagussa, “Dose-Response Effect of Adjuvant Chemotherapy in Breast Cancer,” The New England Journal of Medicine, Vol. 304, 1981, pp. 10-15. http://dx.doi.org/10.1056/ NEJM198101013040103
 G. Tancini, G. Bonadonna, P. Valagussa, S. Marchini and U. Veronesi, “Adjvant CMF in Breast Cancer: Comparative 5-Year Results of 12 versus 6 Cycles,” Journal of Clinical Oncology, Vol. 1, No. 1, 1983, pp. 2-10.
 R. Buzzoni, G. Bonadona, P. Valagussa and M. Zambetti, “Adjuvant Chemotherapy with Doxorubicin plus Cyclophosphamide, Methotrexate, and Fluorouracil in the Treatment of Respectable Breast Cancer with More than Three Positive Axillary Nodes,” Journal of Clinical Oncology, Vol. 9, No. 12, 1991, pp. 2134-2140.
 A. Moliterni, G. Bonadonna, P. Valagussa, L. Ferrari and M. Zambetti, “Cyclophosphamide, Methotrexate, and Fluouracil with and without Doxorubicin in the Adjuvant Treatment of Respectable Breast Cancer with One to Three Positive Axillary Nodes,” Journal of Clinical Oncology, Vol. 9, No. 7, 1991, pp. 1124-1130.
 J. J. Bonenkamp, J. Hermans, M. Sasako, et al., “Extended Lymphnode Dissection for Gastric Cancer,” The New England Journal of Medicine, Vol. 340, No. 12, 1999, pp. 908-914. http://dx.doi.org/ 10.1056/NEJM199903253401202
 I. Songun, H. Putter, E. M. Kranenbarg, M. Sasako and C. J. van de Velde, “Surgical Treatment of Gastric Cancer: 15-Year Follow-Up Results of the Randomized Nationwide Dutch D1D2 Trial,” Lancet Oncology, Vol. 11, No. 5, 2010, pp. 439-449. http://dx.doi.org/10.1016/S1470-2045(10)70070-X
 J. L. Haybittle, “Life Expectancy as a Measurement of the Benefit Shown by Clinical Trials of Treatment for Early Breast Cancer,” Clinical Oncology, Vol. 10, No. 2, 1998, pp. 92-94. http://dx.doi.org/10.1016/S0936-6555(05)80485-6
 J. W. Gamel, R. L. Vogel and I. W. McLean, “Assessing the Impact of Adjuvant Therapy on Cure Rate for Stage 2 Breast Carcinoma,” British Journal of Cancer, Vol. 68, 1993, pp. 115-118. http://dx.doi.org/10.1038/bjc.1993.296
 J. W. Gamel and R. L. Vogel, “Comparison of Parametric and Non-Parametric Survival Methods Using Simulated Clinical Data,” Statistics in Medicine, Vol. 16, No. 14, 1997, pp. 1629-1643. http://dx.doi.org/10.1002/(SICI)1097-0258(19970730)16:14<1629::AID-SIM594>3.0.CO;2-C
 P. Frankel and J. Longmate, “Parametric Models for Accelerated and Long-Term Survival: A Comment on Proportional Hazards,” Statistics in Medicine, Vol. 21, No. 21, 2002, pp. 3279-3289. http://dx.doi.org/10.1002/sim.1273
 S. Maetani, Y. Segawa, H. Banja, et al., “Simulation of Randomized Controlled Trials for Cancer Therapy Using the Boag Model and the Competing Risk Model,” Tenri Medical Bulletin, Vol. 11, No. 1, 2008, pp. 23-48.
 D. K. Heyland, D. Barwich, D. Pichora, et al., “Failure to Engage Hospitalized Elderly Patients and Their Families in Advance Care Planning,” JAMA Internal Medicine, Vol. 173, No. 9, 2013, pp. 778-788.
 J. W. Berg, “Disease-Oriented End Results: A Tool for Pathological-Clinical Analysis,” Cancer, Vol. 17, No. 6, 1964, pp. 693-707. http://dx.doi.org/10.1002/1097-0142(196406)17:6<693::AID-CNCR28 20170603>3.0.CO;2-F
 R. F. Mould and J. W. Boag, “A Test of Several Parametric Statistical Models for Estimating Success Rate in the Treatment of Carcinoma Cervix Uteri,” British Journal of Cancer, Vol. 32, 1975, pp. 529-550. http://dx.doi.org/10.1038/bjc.1975.259
 R. F. Mould, T. Hearnden, M. Palmer and G. C. White, “Distribution of Survival Times of 12,000 Head and Neck Cancer Patients Who Died with Their Disease,” British Journal of Cancer, Vol. 34, 1976, pp. 180-190. http://dx.doi.org/10.1038/bjc.1976.141
 L. E. Rutqvist, A. Wallgren and B. Nilsson, “Is Breast Cancer a Curable Disease? A Study of 14,731 Women with Breast Cancer from the Cancer Registry of Norway,” Cancer, Vol. 53, No. 8, 1984, pp. 1793-1800. http://dx.doi.org/10.1002/1097-0142(19840415)53:8<1793::AID-CNCR2820530832>3.0 .CO;2-Y